Search

Richard J Youle

from Kensington, MD
Age ~71
Get Report
Also known as:
Richard J Wood, Rick J Youle, Dick J Youle, Richard J Yonk, Katherine A Wood
Phone and address:
10213 Montgomery Ave, Kensington, MD 20895
Related to:
Edward Youle, 77Thomas C Youle, 38Elizabeth Youle, 37Katherine A Wood, 62John S Youle, 35Joanna G Greer, 70
Connected to:
Ashley C Youle, 48Steven Youles, 93Jim V Youll, 93Daniel S Youm, 41Amy M Youman, 47Carl A Youman, 57Joshua L Youman, 39Marco C Youman, 50Richard D Youman, 56Andrea Youmans, 35

Richard Youle Phones & Addresses

  • 10213 Montgomery Ave, Kensington, MD 20895
  • 3602 Stewart Dr, Chevy Chase, MD 20815 (301) 718-7823
  • Bethesda, MD
  • Garrett Park, MD

Professional Records

Lawyers & Attorneys

Richard Youle Photo 1

Richard Youle - Lawyer

View page
Office:
Linklaters
Specialties:
Private Equity
ISLN:
920476107
Admitted:
Solicitor of the Senior Courts of England and Wales
University:
Newcastle University, 1995; York College of Law, 1996
Richard Youle Photo 2

Richard Youle - Lawyer

View page
Specialties:
European Private Equity
Private Equity
ISLN:
923054761
Admitted:
Senior Courts of England & Wales

Business Records

Name / Title
Company / Classification
Phones & Addresses
Richard Youle
Nih/ninds/director/cnp
U S Dept of Health and Human Services
Associations
200 Independence Ave SW, Washington, DC 20201
900 2 St NE #211, Washington, DC 20201
(202) 619-0257, (202) 408-9520

Publications

Us Patents

Mutant Form Of A Cytotoxic Ribonucleolytic Protein Which Allows Production By Recombinant Methods

View page
US Patent:
6649392, Nov 18, 2003
Filed:
Apr 4, 1996
Appl. No.:
08/626288
Inventors:
Richard J. Youle - Bethesda MD
Veena M. Vasandani - Rockville MD
Ester Boix - Barcelona, ES
Wojciech Ardelt - New City NY
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
C12N 922
US Classification:
435199, 536 232, 536 231
Abstract:
The present invention provides recombinant Onc (rOnc) compositions and methods. Recombinant Onc proteins of the invention have an amino terminal methionine and comprise an Onc polypeptide. The amino terminal methionine of the protein allows for recombinant production in a bacterial host cell. Cleaving the amino terminal methionine exposes the amino terminal glutamine of the polypeptide. The Onc polypeptide has an amino terminal glutamine. Cyclization of the amino terminal glutamine of the polypeptide to a pyroglutamyl residue provides rOnc polypeptides and proteins have anti-cancer and anti-viral activity.

Mutant Form Of Cytotoxic Ribonucleolytic Protein Which Allows Production By Recombinant Methods

View page
US Patent:
6649393, Nov 18, 2003
Filed:
Jun 10, 1998
Appl. No.:
09/095429
Inventors:
Richard J. Youle - Bethesda MD
Veena M. Vasandani - Rockville MD
Ester Boix - Barcelona, ES
Wojciech Ardelt - New City NY
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
C12N 922
US Classification:
435199, 43525233, 4353201, 536 232, 536 231, 536 235
Abstract:
The present invention provides recombinant Onc (rOnc) compositions and methods. Recombinant Onc proteins of the invention have an amino terminal methionine and comprise an Onc polypeptide. The amino terminal methionine of the protein allows for recombinant production in a bacterial host cell. Cleaving the amino terminal methionine exposes the amino terminal glutamine of the polypeptide. The Onc polypeptide has an amino terminal glutamine. Cyclization of the amino terminal glutamine of the polypeptide to a pyroglutamyl residue provides rOnc polypeptides and proteins have anti-cancer and anti-viral activity.

Methods Of Protecting Vasculature From Damage By Diphtheria Toxin-And Pseudomonas Toxin-Based Immunotoxins During Therapy

View page
US Patent:
6696064, Feb 24, 2004
Filed:
Jun 19, 2001
Appl. No.:
09/884695
Inventors:
Richard J. Youle - Chevy Chase MD
Naoshi Hagihara - Saga, JP
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
A61K 3902
US Classification:
4242341, 4242361, 4242451, 4242601, 514 1, 514 2
Abstract:
Vascular damage has proven to be dose limiting in administering immunotoxins into the brain to treat brain tumors. Vascular toxicity of immunotoxins which rely in part on exposure to lowered pH in cellular endosomes and lysosomes can be avoided by administering an endosome pH-raising agent systemically during some or all of the time that the immunotoxin is present in the brain of the organism. Suitable endosome pH-raising agents include lysosomotrophic amines, proton ionophores, and vacuolar H+ ATPase inhibitors. The invention increases the therapeutic window of the immunotoxins and increases the likelihood the treatment will have an effect on the course of the tumor.

Receptor-Mediated Uptake Of An Extracellular Bcl-Xl Fusion Protein Inhibits Apoptosis

View page
US Patent:
6737511, May 18, 2004
Filed:
Aug 15, 2000
Appl. No.:
09/639245
Inventors:
Richard J. Youle - Chevy Chase MD
R. John Collier - Wellesley MA
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
C07K 1400
US Classification:
530350, 530351, 5303873, 5303877, 5303881, 5303888, 435 691, 435 695, 435 697, 435 713, 4241341, 4241381, 4241411, 4242361, 4242381
Abstract:
Apoptosis-modifying fusion polypeptides, and the corresponding nucleic acid molecules, are disclosed. Pharmaceutical compositions comprising these polypeptides, and the use of these polypeptides to modify apoptosis are also provided.

Immunotoxin (Mab-Ricin) For The Treatment Of Focal Movement Disorders

View page
US Patent:
6780413, Aug 24, 2004
Filed:
Nov 7, 2001
Appl. No.:
10/005512
Inventors:
Jonathan S. Hott - Birmingham MI
Richard J. Youle - Bethesda MD
Mark Hallett - Bethesda MD
Marinos C. Dalakas - Bethesda MD
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
A61K 39395
US Classification:
4241431, 4241831
Abstract:
Compositions and methods for treatment of focal muscle spasms. Immunotoxin conjugates comprise a toxin conjugated to an antibody reactive to a muscle specific antigen.

Receptor-Mediated Uptake Of An Extracellular Bcl-Xl Fusion Protein Inhibits Apoptosis

View page
US Patent:
20040152179, Aug 5, 2004
Filed:
Mar 2, 2004
Appl. No.:
10/792517
Inventors:
Richard Youle - Chevy Chase MD, US
R. Collier - Wellesley MA, US
Assignee:
The Government of the U.S.A. as represented by the Secretary of the Dept. of Health & Human Services
International Classification:
C12N009/99
US Classification:
435/184000
Abstract:
Apoptosis-modifying fusion polypeptides, and the corresponding nucleic acid molecules, are disclosed. Pharmaceutical compositions comprising these polypeptides, and the use of these polypeptides to modify apoptosis are also provided.

Immunotoxin (Mab-Ricin) For The Treatment Of Focal Movement Disorders

View page
US Patent:
20050266010, Dec 1, 2005
Filed:
Jul 9, 2004
Appl. No.:
10/886557
Inventors:
Jonathan Hott - Birmingham MI, US
Richard Youle - Bethesda MD, US
Mark Hallett - Bethesda MD, US
Marinos Dalakas - Bethesda MD, US
International Classification:
A61K039/395
A61K035/78
US Classification:
424178100, 424731000
Abstract:
Compositions and methods for treatment of focal muscle spasms. Immunotoxin conjugates comprise a toxin conjugated to an antibody reactive to a muscle specific antigen.

Receptor-Mediated Uptake Of An Extracellular Bcl-Xl Fusion Protein Inhibits Apoptosis

View page
US Patent:
20070243190, Oct 18, 2007
Filed:
Mar 27, 2007
Appl. No.:
11/692112
Inventors:
Richard Youle - Chevy Chase MD, US
R. Collier - Wellesley MA, US
International Classification:
C07K 14/34
A61K 38/00
A61K 39/00
C07K 14/435
C07K 14/47
C07K 14/00
C07K 14/195
US Classification:
424134100, 424138100, 424141100, 424236100, 424238100, 435069100, 435069500, 435069700, 435071300, 530351000, 530387300, 530387700, 530388100, 530388800
Abstract:
Apoptosis-modifying fusion polypeptides, and the corresponding nucleic acid molecules, are disclosed. Pharmaceutical compositions comprising these polypeptides, and the use of these polypeptides to modify apoptosis are also provided.
Control profile
Richard J Youle from Kensington, MD, age ~71 Get Report